Literature DB >> 7981019

Guidelines for company-sponsored Safety Assessment of Marketed Medicines (SAMM) guidelines. Medicines Control Agency, Committee on Safety of Medicines, Royal College of General Practitioners, British Medical Association and Association of the British Pharmaceutical Industry (November 1993)

.   

Abstract

Mesh：

Year:  1994        PMID： 7981019      PMCID： PMC1364852          DOI： 10.1111/j.1365-2125.1994.tb04330.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN： 0306-5251            Impact factor:   4.335


× No keyword cloud information.
  1 in total

1.  Review of company postmarketing surveillance studies.

Authors:  P C Waller; S M Wood; M J Langman; A M Breckenridge; M D Rawlins
Journal:  BMJ       Date:  1992-06-06
  1 in total
  5 in total

1.  Postmarketing surveillance study of a non-chlorofluorocarbon inhaler. Such studies initiated by manufacturer are designed to promote product.

Authors:  M G Bamber
Journal:  BMJ       Date:  1999-03-20

Review 2.  Pharmacovigilance in the pharmaceutical industry.

Authors:  J C Talbot; B S Nilsson
Journal:  Br J Clin Pharmacol       Date:  1998-05       Impact factor: 4.335

3.  Prescribing patterns in patients using new antidepressants.

Authors:  W E Meijer; E R Heerdink; L P Pepplinkhuizen; J T van Eijk; H G Leufkens
Journal:  Br J Clin Pharmacol       Date:  2001-02       Impact factor: 4.335

4.  Determinants of headache in lansoprazole users in The Netherlands: results from a nested case-control study.

Authors:  Angela A M C Claessens; Eibert R Heerdink; Jacques T H M van Eijk; Cornelis B H W Lamers; Hubert G M Leufkens
Journal:  Drug Saf       Date:  2002       Impact factor: 5.606

5.  Mortality study of 18 000 patients treated with omeprazole.

Authors:  D N Bateman; D Colin-Jones; S Hartz; M Langman; R F Logan; J Mant; M Murphy; K R Paterson; R Rowsell; S Thomas; M Vessey
Journal:  Gut       Date:  2003-07       Impact factor: 23.059
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.